Alternative splicing in prostate and breast cancer

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 62-76

  Watson, Patricia M ^a   Watson, Dennis K ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Androgen receptor; BRCA1; Estrogen receptor; Exon arrays; Extracellular matrix; Growth factor receptors; RNASeq; Spliceosome

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA ACTININ 1; ALPHA TROPOMYOSIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ATM PROTEIN; BRCA1 PROTEIN; CASPASE 3; CYCLIN D1; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN MCL 1; SURVIVIN; TAU PROTEIN; TRANSCRIPTION FACTOR ETS 1; UNINDEXED DRUG; VASCULOTROPIN; VINCULIN; VON HIPPEL LINDAU PROTEIN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; DRUG RESPONSE; EXTRACELLULAR MATRIX; HUMAN; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE SURGERY; SPLICEOSOME;

EID: 78249278489     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010062     Document Type: Article

References (122)

1. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6: 386-98.
2. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8: 349-57.
3. Smith DJ, Query CC, Konarska MM. Nought may endure but mutability: spliceosome dynamics and the regulation of splicing. Mol Cell 2008; 30: 657-66.
4. Johnson JM, Castle J, Garrett-Engele P, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003; 302: 2141-4.
5. Lee JH, Horak CE, Khanna C, et al. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Cancer Res 2008; 68: 639-44.
6. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Ann Rev Biochem 2003; 72: 291-336.
7. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-54.
8. Broeks A, Urbanus JH, de Knijff P, et al. IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer. Hum Mutat 2003; 21: 521-8.
9. Hoffman JD, Hallam SE, Venne VL, Lyon E, Ward K. Implications of a novel cryptic splice site in the BRCA1 gene. Am J Med Genet 1998; 80: 140-4.
10. Shoemaker DD, Schadt EE, Armour CD, et al. Experimental annotation of the human genome using microarray technology. Nature 2001; 409: 922-7.
11. Fehlbaum P, Guihal C, Bracco L, Cochet O. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucl Acids Res 2005; 33: e47.
12. Andre F, Michiels S, Dessen P, et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009; 10: 381-90.
13. Klinck R, Bramard A, Inkel L, et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res 2008; 68: 657-63.
14. Li HR, Wang-Rodriguez J, Nair TM, et al. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 2006; 66: 4079-88.
15. Venables JP, Klinck R, Bramard A, et al. Identification of alternative splicing markers for breast cancer. Cancer Res 2008; 68: 9525-31.
16. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-5.
17. Sultan M, Schulz MH, Richard H, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008; 321: 956-60.
18. Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-6.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
20. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
21. Heidenreich A, Aus G, Bolla M, et al. [EAU guidelines on prostate cancer]. Actas Urol Esp 2009; 33: 113-26.
22. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14: 2410-34.
23. van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 2007; 61: 104-39.
24. Hirata H, Hinoda Y, Kawamoto K, et al. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J Urol 2008; 179: 2020-4.
25. Prtilo A, Leach FS, Markwalder R, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 2005; 174: 1814-8; discussion 8.
26. Thorsen K, Sorensen KD, Brems-Eskildsen AS, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008; 7: 1214-24.
27. Zhang C, Li HR, Fan JB, et al. Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006; 7: 202.
28. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447- 54.
29. Jagla M, Feve M, Kessler P, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007; 148: 4334- 43.
30. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-77.
31. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
32. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001; 58: 289-94.
33. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. Heteroge- neous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002; 161: 1467-74.
34. Linja MJ, Porkka KP, Kang Z, et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10: 1032-40.
35. Mestayer C, Blanchere M, Jaubert F, Dufour B, Mowszowicz I. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 2003; 56: 192-200.
36. Miyoshi Y, Ishiguro H, Uemura H, et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003; 56: 280-6.
37. Tekur S, Lau KM, Long J, Burnstein K, Ho SM. Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Mol Carcinog 2001; 30: 1-13.
38. Hosoya T, Monden T, Fukabori Y, et al. A novel splice variant of the nuclear coactivator p120 functions strongly for androgen receptor: characteristic expression in prostate disease. Endocr J 2008; 55: 657-65.
39. Nakaya HI, Beckedorff FC, Baldini ML, Fachel AA, Reis EM, Verjovski-Almeida S. Splice variants of TLE family genes and up- regulation of a TLE3 isoform in prostate tumors. Biochem Biophys Res Commun 2007; 364: 918-23.
40. Jin R, Trikha M, Cai Y, Grignon D, Honn KV. A naturally occurring truncated beta3 integrin in tumor cells: native anti- integrin involved in tumor cell motility. Cancer Biol Ther 2007; 6: 1559-68.
41. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997; 50: 57-71.
42. Afify A, Purnell P, Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009; 86: 95-100.
43. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991; 10: 343-8.
44. Bennett KL, Modrell B, Greenfield B, et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995; 131: 1623-33.
45. Bartolazzi A, Jackson D, Bennett K, et al. Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci 1995; 108 (Pt 4): 1723-33.
46. Iczkowski KA, Omara-Opyene AL, Shah GV. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res 2006; 26: 2863-72.
47. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer 2008; 8: 260.
48. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-62.
49. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997; 32: 140-8.
50. Cao KY, Mao XP, Wang DH, et al. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 2007; 67: 1791-800.
51. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14: 4719- 25.
52. Yeh BK, Igarashi M, Eliseenkova AV, et al. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci USA 2003; 100: 2266-71.
53. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997; 15: 3059-65.
54. Hayes NV, Blackburn E, Smart LV, et al. Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer. Clin Cancer Res 2007; 13: 3147-55.
55. Wang R, Xu J, Saramaki O, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res 2004; 64: 1589-94.
56. Wang R, He H, Sun X, et al. Transcription variants of the prostate- specific PrLZ gene and their interaction with 14-3-3 proteins. Biochem Biophys Res Commun 2009; 389: 455-60.
57. Vanessa K de Sa, Flávio C. Canavez, Iran A. Silva, Miguel S, Katia R.M. Leite. Isoforms of hyaluronidases can be a predictor of a prostate cancer of good prognosis. Urologic Oncol 2009; 27.
58. Lokeshwar VB, Schroeder GL, Carey RI, Soloway MS, Iida N. Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 2002; 277: 33654-63.
59. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK. Evaluation of survivin reverse transcriptase- polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 2006; 175: 2312-6.
60. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
61. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11.
62. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008; 72: 1229-33.
63. Kim MH. Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J Cell Biochem 2008; 104: 1491-9.
64. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-202.
65. Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2008; 11: 94-8.
66. Vakar-Lopez F, Cheng CJ, Kim J, et al. Up-regulation of MDA- BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 2004; 203: 688-95.
67. Lin SH, Cheng CJ, Lee YC, et al. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 2008; 27: 5195-203.
68. Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett 2008; 271: 13-24.
69. Heuze-Vourc'h N, Leblond V, Courty Y. Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur J Biochem 2003; 270: 706-14.
70. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12: 1-7.
71. Catena R, Muniz-Medina V, Moralejo B, et al. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int J Cancer 2007; 120: 2096-109.
72. Rajan P, Gaughan L, Dalgliesh C, et al. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 2008; 215: 67-77.
73. Ribeiro FR, Diep CB, Jeronimo C, et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006; 45: 154-63.
74. Ribeiro FR, Jeronimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006; 12: 3961-70.
75. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-68.
76. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
77. Escot C, Theillet C, Lidereau R, et al. Genetic alteration of the c- myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 1986; 83: 4834-8.
78. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. p53 alterations in all stages of breast cancer. J Surg Oncol 1991; 48: 260-7.
79. Venables JP, Klinck R, Koh C, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670-6.
80. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Ann Rev Physiol 2001; 63: 165-92.
81. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol 2005; 19: 1555-68.
82. Stevens TA, Meech R. BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion. Oncogene 2006; 25: 5426-35.
83. Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)- beta reduces ERalpha-regulated gene transcription, supporting a ying yang relationship between ERalpha and ERbeta in mice. Mol Endocrinol 2003; 17: 203-8.
84. LaVoie HA, DeSimone DC, Gillio-Meina C, Hui YY. Cloning and characterization of porcine ovarian estrogen receptor beta isoforms. Biol Reprod 2002; 66: 616-23.
85. Treeck O, Pfeiler G, Horn F, et al. Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol Cell Endocrinol 2007; 264: 50-60.
86. Cork DM, Lennard TW, Tyson-Capper AJ. Alternative splicing and the progesterone receptor in breast cancer. Breast Cancer Res 2008; 10: 207.
87. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177- 82.
88. Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 1999; 96: 10869-74.
89. Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, Kotoula V. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia 2008; 10: 687-96.
90. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol 2003; 56: 191-7.
91. Hurst LD, Pal C. Evidence for purifying selection acting on silent sites in BRCA1. Trends Genet 2001; 17: 62-5.
92. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996; 13: 1-7.
93. Yuli C, Shao N, Rao R, et al. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene 2007; 26: 6031- 7.
94. Maniccia AW, Lewis C, Begum N, et al. Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins. J Cell Physiol 2009; 219: 634-41.
95. Hancox RA, Allen MD, Holliday DL, et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009; 11: R24.
96. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162: 127-33.
97. Terpe HJ, Stark H, Prehm P, Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 1994; 101: 79-89.
98. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424-33.
99. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-6.
100. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009; 23: 285-91.
101. Blaustein M, Pelisch F, Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol 2007; 39: 2031-48.
102. Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase- interacting kinases (MAP kinase signal-integrating kinases). Front Biosci 2008; 13: 5359-73.
103. Lammers T, Lavi S. Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. Crit Rev Biochem Mol Biol 2007; 42: 437-61.
104. Leeman JR, Gilmore TD. Alternative splicing in the NF-kappaB signaling pathway. Gene 2008; 423: 97-107.
105. Suh PG, Park JI, Manzoli L, et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep 2008; 41: 415-34.
106. Williams T, Kole R. Analysis of prostate-specific membrane antigen splice variants in LNCap cells. Oligonucleotides 2006; 16: 186-95.
107. Haudenschild DR, Curtiss SB, Moseley TA, Reddi AH. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate 2006; 66: 1268-74.
108. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 2007; 103: 334-7.
109. Hernandez M, Almeida TA. Is there any association between nek3 and cancers with frequent 13q14 deletion? Cancer Invest 2006; 24: 682-8.
110. Gallo RM, Bryant I, Fry R, Williams EE, Riese DJ, 2nd. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun 2006; 349: 372-82.
111. Mayer S, zur Hausen A, Watermann DO, et al. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 2008; 134: 1229-35.
112. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6: 435-45.
113. Muraoka-Cook RS, Sandahl MA, Strunk KE, et al. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol 2009; 29: 4935-48.
114. Cooper C, Guo J, Yan Y, et al. Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Res 2009; 37: 4518-31.
115. Laitem C, Leprivier G, Choul-Li S, et al. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51. Oncogene 2009; 28: 2087-99.
116. Hirschfeld M, zur Hausen A, Bettendorf H, Jager M, Stickeler E. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 2009; 69: 2082- 90.
117. Wang Y, Dean JL, Millar EK, et al. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68: 5628-38.
118. He W, Parker R. Functions of Lsm proteins in mRNA degradation and splicing. Curr Opin Cell Biol 2000; 12: 346-50.
119. Mirza M, Shaughnessy E, Hurley JK, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122: 889-97.
120. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 2007; 104: 5575-9.
121. Vegran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard- Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12: 5794-800.
122. Cordes T, Diesing D, Becker S, Fischer D, Diedrich K, Friedrich M. Expression of splice variants of 1alpha-hydroxylase in mcf-7 breast cancer cells. J Steroid Biochem Mol Biol 2007; 103: 326-9.